TS-161, a drug blocking mGlu2/3 receptors, may help treat hard-to-treat depression: Early clinical trial results

A phase I trial of the mGluR2/3 antagonist prodrug TS-161 demonstrated its safety and tolerability.

• TS-161 is associated with increased glutamate release and enhanced signaling related to mood regulation.
• The drug may promote synaptic plasticity, a process important for learning and memory.
• Results from preclinical models suggest that TS-161 exhibits antidepressant-related activity.

Simplified